RxDoctor Payments Data

Candace Mangum

Primary Care · Tuskegee, ALNPI 1407924384

Payments from drug & device makers

$840in general payments, 2019–2025

Across 34 payments — averaging $24.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$186
  • GSK$157
  • Lilly USA, LLC$111
  • Inspire Medical Systems, Inc.$66
  • Pfizer$63
  • Astellas Pharma US Inc$47
  • plus $210 from 9 others

What the payments were for

  • Food & beverage$840100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$840 in reported general payments places this provider in the 50th percentile of 159 primary care providers in Alabama.

See all primary care providers in Alabama

Medicare billing

Part B allowed, 2024
$294
Medicare patients
17
Services billed
23

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide71$62,166
EliquisApixaban39$44,029
JanuviaSitagliptin Phosphate36$43,180
OzempicSemaglutide40$40,289
FarxigaDapagliflozin Propanediol31$29,983
MounjaroTirzepatide26$27,123
Breo ElliptaFluticasone/Vilanterol49$24,806
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$22,812
TrulicityDulaglutide14$12,995
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$9,591
SymbicortBudesonide/Formoterol Fumarate34$7,658
Combivent RespimatIpratropium/Albuterol Sulfate11$7,492
Albuterol Sulfate HfaAlbuterol Sulfate284$6,442
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$6,130
Spiriva HandihalerTiotropium Bromide12$5,779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Trelegy Ellipta$157$47,61872 claims
PfizerEliquis$63$44,02939 claims
AstraZenecaFarxiga, Symbicort, Brilinta$186$43,20377 claims
Lilly USA, LLCMounjaro, Trulicity$111$40,11840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 159 primary care providers in Alabama.

Other primary care in Tuskegee

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →